Tiny implant could track oxygen in legs of PAD patients
NCT ID NCT04514861
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new wireless sensor that is injected under the skin to measure oxygen levels in the legs of people with peripheral artery disease (PAD). The sensor tracks how oxygen changes when blood flow is altered by a pressure cuff or changing position. Researchers want to see if this device works as well as current methods. Fifty-three adults with stable PAD will be followed for 12 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 53 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2020
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: A suitable candidate must meet the following criteria: * Male or female must be ≥ 18 years of age * Diagnosed with PAD, stable at time of enrollment, and may include prior stable lower extremity revascularization * Has been informed of the nature of the study, agrees to its provisions, and has signed the informed consent form prior to any study related procedure * Should plan to be available for all safety follow-up examinations at the investigational site * Is aware that the Lumee™ Oxygen hydrogels are intended to stay in the tissue indefinitely * Is aware that photos of injection sites and wound site will be taken, and videos may be recorded Exclusion Criteria: A candidate will be excluded from the study if any of the following criteria are met: * PAD of Rutherford Classification 5 or 6 at time of enrollment * Subject has an active infection * Subject has an open wound on limb included in study * Known history of keloids, excessive fibrosis during wound healing * Known allergies to Lumee™ Oxygen hydrogel components, local anesthetic agents, suture materials, or severe skin allergies to adhesives * Any skin or musculoskeletal condition or deformity limiting injection of the Lumee™ Oxygen hydrogel or preventing subsequent attachments of the Lumee™ Patch system * Any skin modification in the area of injection that would potentially influence device performance (for example tattoos or scars) * Previous amputation proximal to the digital level on the limb included in the study * Significant venous insufficiency resulting in swelling of the lower leg, ankle or foot or chronic venous stasis changes (CEAP clinical score ≥ 3) * Any condition that at the discretion of the investigator, physician or designee will impact the safety of the subject or the scientific integrity of the trial * Female subjects of childbearing capacity (not surgically sterile or menopausal for ≥ 1 year) * Participation in another clinical study, that would potentially interfere with the participation in this study * Subject requires dialysis * Subject is immunocompromised * Subject has incompressible arteries tested by occlusion test in the arm * Inability to obtain consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Peripheral artery disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
San Francisco General Hospital
San Francisco, California, 94110, United States
-
San Francisco Veterans Affairs Medical Center (SFVAMC)
San Francisco, California, 94121, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a rotating device plus a debris filter keep leg arteries open longer?
- Can a standard blood thinner match a newer combo for preventing heart attacks?
- Could artery disease drain the body's repair cells?
- FitBit coaching may help amputees walk more after surgery
- Can a novel device change treatment? a trial seeks answers
- A simple handheld test could spot hidden artery trouble in diabetic foot wounds